Paul H. Gumerlock

7.3k citations

146 papers · 5.9k indexed · 1 hit paper · h-index 41

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Lung Cancer Diagnosis and Treatment

Papers in

Oncology 84
- Cancer-related Molecular Pathways 39
- Peptidase Inhibition and Analysis 16
- Lung Cancer Research Studies 13
- Colorectal Cancer Treatments and Studies 10
Pulmonary and Respiratory Medicine 65
- Lung Cancer Treatments and Mutations 38
- Prostate Cancer Treatment and Research 15

Co-authors: David R. Gandara Primo N. Lara Frederick J. Meyers Ralph W. deVere White Philip C. Mack Howard West Angela M. Davies John Crowley
Journals: Journal of Clinical Oncology (29 papers)Cancer (9 papers)Lung Cancer (8 papers)Clinical Lung Cancer (8 papers)Journal of Thoracic Oncology (7 papers)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Paul H. Gumerlock

144 papers receiving 5.7k citations

Hit Papers

align trajectories log scale

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. 2002 · 551 citations

Peers

Countries citing papers authored by Paul H. Gumerlock

Since Specialization

Citations

This map shows the geographic impact of Paul H. Gumerlock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul H. Gumerlock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul H. Gumerlock more than expected).

Fields of papers citing papers by Paul H. Gumerlock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul H. Gumerlock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul H. Gumerlock. The network helps show where Paul H. Gumerlock may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul H. Gumerlock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul H. Gumerlock Line = papers co-authored together Paul H. Gumerlock links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339) Journal of Thoracic Oncology ·Angela M. Davies, Kari Chansky, Primo N. Lara, Paul H. Gumerlock, John Crowley, Kathy S. Albain, Stanley Vogel, David R. Gandara	2009	64
2	Origin and prognostic value of circulating KRAS mutations in lung cancer patients Cancer Letters ·Oliver Gautschi, Barbara Huegli, Annemarie Ziegler, Mathias Gugger, Jim Heighway, Daniel Ratschiller, Philip C. Mack, Paul H. Gumerlock, Hsing‐Jien Kung, Rolf A. Stahel, David R. Gandara, Daniel Betticher	2007	78
3	Enhancing the anticancer activity of paclitaxel through cyclin-dependent kinase inhibition Cancer Research ·Philip C. Mack, Christopher M. Mahaffey, Paul H. Gumerlock, David R. Gandara	2004	1
4	Trastuzumab plus Docetaxel in HER2/neu–Positive Non–Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial Clinical Lung Cancer ·Primo N. Lara, Luko Laptalo, Jeff Longmate, Derick Lau, Regina Gandour‐Edwards, Paul H. Gumerlock, James H. Doroshow, David R. Gandara	2004	83
5	Mutant DNA in Plasma of Lung Cancer Patients: Potential for Monitoring Response to Therapy Annals of the New York Academy of Sciences ·Tatsuo Kimura, Will S. Holland, Tomoya Kawaguchi, Stephen K. Williamson, Kari Chansky, John J. Crowley, James H. Doroshow, Heinz-Josef Lenz, David R. Gandara, Paul H. Gumerlock	2004	40
6	Enhancement of Radiation Cytotoxicity by UCN-01 in Non-small Cell Lung Carcinoma Cells Radiation Research ·Philip C. Mack, Angela A. Jones, Matthew H. Gustafsson, David R. Gandara, Paul H. Gumerlock, Zelanna Goldberg	2004	12
7	SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. PubMed ·Primo N. Lara, David I. Quinn, Kim Margolin, Frederick J. Meyers, Jeff Longmate, Paul Frankel, Philip C. Mack, Corinne Turrell, Peter J.M. Valk, Jyotsna Rao, Penelope Buckley, Theodore Wun, Robert C. Gosselin, Irina Galvin, Paul H. Gumerlock, Heinz Josef Lenz, James H. Doroshow, David R. Gandara	2003	51
8	Methods for Isolation and Genetic Analysis of Circulating Tumor DNA in Patient Plasma Humana Press eBooks ·Tomoya Kawaguchi, Will S. Holland, Paul H. Gumerlock	2003	4
9	BCL2 Antisense Reduces Prostate Cancer Cell Survival Following Irradiation Cancer Biotherapy and Radiopharmaceuticals ·Susan Scott, Roger Higdon, Laurel Beckett, Xu-Bao Shi, Ralph W. deVere White, John D. Earle, Paul H. Gumerlock	2002	17
10	Application of a Yeast Assay to Detect Functional p53 Mutations in Archival Prostate Cancer Tissue Cancer Biotherapy and Radiopharmaceuticals ·Xu-Bao Shi, Stephen M. Di Mauro, Ralph A. Highshaw, Arline D. Deitch, Christopher P. Evans, Paul H. Gumerlock, Ralph W. deVere White	2002	6
11	BCL2 Antisense Transcripts Decrease Intracellular Bcl2 Expression and Sensitize LNCaP Prostate Cancer Cells to Apoptosis-Inducing Agents Cancer Biotherapy and Radiopharmaceuticals ·Xu-Bao Shi, Paul H. Gumerlock, Jared T. Muenzer, Ralph W. deVere White	2001	4
12	Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using ⁶⁷ Cu-2IT-BAT-Lym-1 Radioimmunotherapy Cancer Biotherapy and Radiopharmaceuticals ·Linda A. Kroger, Gerald L. DeNardo, Paul H. Gumerlock, Cheng Xiong, Michelle D. Winthrop, Xu Shi, Philip C. Mack, Tatiana V. Leshchinsky, Sally J. DeNardo	2001	35
13	Critical Lym-1 binding residues on polymorphic HLA-DR molecules Molecular Immunology ·Larry Rose, C.-T. Deng, Susan Scott, C. Xiong, Kathleen R. Lamborn, Paul H. Gumerlock, Gerald L. DeNardo, Claude F. Meares	1999	23
14	Use of a yeast assay to detect functional alterations inp53 in prostate cancer: Review and future directions The Prostate ·Ralph W. deVere White, Arline D. Deitch, Paul H. Gumerlock, Xu-Bao Shi	1999	12
15	Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region Cancer ·Kim Deckard-Janatpour, Raymond L. Teplitz, Byung Hee Min, Boris H. Ruebner, Paul H. Gumerlock	1998	5
16	Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells Molecular Endocrinology ·Jiann-an Tan, Yousuf Sharief, Katherine G. Hamil, Christopher W. Gregory, De-Ying Zang, Madhabananda Sar, Paul H. Gumerlock, Ralph W. deVere White, Thomas G. Pretlow, Stephen E. Harris, Elizabeth M. Wilson, James L. Mohler, Frank S. French	1997	288
17	Toxicity of Cationic Lipid–Ribozyme Complexes in Human Prostate Tumor Cells Can Mimic Ribozyme Activity Biochemical and Molecular Medicine ·Stephen J. Freedland, Robert W. Malone, Holger M. Borchers, Zhanna Zadourian, Jill Glasspool‐Malone, Malcolm J. Bennett, Michael H. Nantz, Juan-Hua Li, Paul H. Gumerlock, Kent L. Erickson	1996	24
18	Identification of p53 Mutations in Archival Prostate Tumors Diagnostic Molecular Pathology ·Xu Shi, Sara M. Bodner, Ralph W. deVere White, Paul H. Gumerlock	1996	14
19	Genotyping of Clostridium difficile Isolates The Journal of Infectious Diseases ·Joseph Silva, Y J Tang, Paul H. Gumerlock	1994	29
20	Rapid PCR construction of a gene containing Lym-1 antibody variable regions. Genome Research ·Xu Shi, Paul H. Gumerlock, Arthur Wellman, Claude F. Meares, Gerald L. DeNardo, Frederick J. Meyers, Sally J. DeNardo	1993	4

About Paul H. Gumerlock

Paul H. Gumerlock is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Molecular Biology, having authored 146 papers that have together received 5.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (39 papers), Lung Cancer Treatments and Mutations (38 papers), Ubiquitin and proteasome pathways (20 papers), Peptidase Inhibition and Analysis (16 papers), Prostate Cancer Treatment and Research (15 papers), Cancer Genomics and Diagnostics (14 papers), Lung Cancer Research Studies (13 papers) and Colorectal Cancer Treatments and Studies (10 papers). The work is most often cited by research in Oncology (3.0k citations), Pulmonary and Respiratory Medicine (3.3k citations), Cancer Research (1.1k citations), Molecular Biology (2.4k citations) and Pathology and Forensic Medicine (466 citations). Paul H. Gumerlock has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include David R. Gandara, Primo N. Lara, Frederick J. Meyers, Ralph W. deVere White, Philip C. Mack, Howard West, Angela M. Davies, John Crowley, Wilbur A. Franklin and Kari Chansky. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Lung Cancer, Clinical Lung Cancer and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact